Cargando…
Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience
PURPOSE: Several targeted agents demonstrated efficacy in early clinical trials for gastrointestinal (GI) cancers, but in many cases, phase-III trials and/or approval by the European Medicines Agency (EMA) are lacking. The primary focus of this study was to assess the regulatory processes associated...
Autores principales: | Welland, Sabrina, deCastro, Tiago, Bathon, Melanie, Wirth, Thomas Christian, Reineke-Plaaß, Tanja, Saborowski, Michael, Lehmann, Ulrich, Saborowski, Anna, Vogel, Arndt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293869/ https://www.ncbi.nlm.nih.gov/pubmed/34436668 http://dx.doi.org/10.1007/s00432-021-03774-5 |
Ejemplares similares
-
Atezolizumab and bevacizumab in patients with advanced hepatocellular
carcinoma with impaired liver function and prior systemic therapy: a real-world
experience
por: de Castro, Tiago, et al.
Publicado: (2022) -
FGFR inhibitors in cholangiocarcinoma: what’s now and what’s
next?
por: Saborowski, Anna, et al.
Publicado: (2020) -
Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research
por: Erice, Oihane, et al.
Publicado: (2019) -
Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer
por: Erlangga, Zulrahman, et al.
Publicado: (2019) -
Resource misallocation and productivity
por: Misch, Florian, et al.
Publicado: (2018)